{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477240986
| IUPAC_name = ''N''-{2-[bis(1-Methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide
| image = Acotiamide.svg
| width = 275

<!--Clinical data-->
| tradename = Acofide ([[Japan|JP]])
| pregnancy_category =
| legal_US_comment = Not approved  
| legal_status = Rx-only ([[Japan|JP]])
| routes_of_administration = [[Oral administration|By mouth]] ([[Tablet (pharmacy)|tablets]])

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 84.21–85.95%
| metabolism = [[UGT1A8]] and [[UGT1A9|1A9]] (major)
| elimination_half-life = 10.9–21.7 hours
| excretion = Feces (92.7%), urine (5.3%)<ref>{{cite web|title=Acofide (acotiamide hydrochloride hydrate) Tablets Review Report|url=https://www.pmda.go.jp/files/000153467.pdf|accessdate=29 December 2016}}</ref>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 185106-16-5
| ATC_prefix = None
| ATC_suffix =
| PubChem = 5282338
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4445505
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2107723
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D42OWK5383
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08838

<!--Chemical data-->
| C=21 | H=30 | N=4 | O=5 | S=1 
| molecular_weight = 450.55 g/mol
| smiles = O=C(Nc1nc(C(=O)NCCN(C(C)C)C(C)C)cs1)c2cc(OC)c(OC)cc2O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = TWHZNAUBXFZMCA-UHFFFAOYSA-N
}}

'''Acotiamide''' (brand name '''Acofide''', codenamed '''YM-443''' and '''Z-338''') is a drug approved in Japan for the treatment of [[postprandial]] fullness, upper abdominal [[bloating]], and early [[Satiety|satiation]] due to [[functional dyspepsia]].<ref>{{cite journal | last1 = Matsueda | first1 = K | last2 = Hongo | first2 = M | last3 = Tack | first3 = J | last4 = Aoki | first4 = H | last5 = Saito | first5 = Y | last6 = Kato | first6 = H | title = Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients withfunctional dyspepsia – 100 mg t.i.d. is an optimal dosage | journal = Neurogastroenterology and Motility: The Official Journal of the European Gastrointestinal Motility Society | date = June 2010 | volume = 22 | issue = 6 | pages = 618-e173 | doi = 10.1111/j.1365-2982.2009.01449.x | pmid = 20059698 | url = http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2982.2009.01449.x/epdf}}</ref> It acts as an [[acetylcholinesterase inhibitor]]. It is pending approval in the United States; ten clinical trials have been successfully completed.

== References ==
{{Reflist}}

{{Drugs for functional gastrointestinal disorders}}
{{Acetylcholine metabolism and transport modulators}}

[[Category:Acetylcholinesterase inhibitors]]
[[Category:Amines]]
[[Category:Phenol ethers]]
[[Category:Salicylamides]]
[[Category:Thiazoles]]

{{gastrointestinal-drug-stub}}
{{amine-stub}}